Subcutaneous immunoglobulin replacement therapy in patients with primary immunodeficiency in routine clinical practice: the VISPO prospective multicenter study.

Clin Drug Investig · 2015 · PMC4335091 · PMID 25672929

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

slightly non-significantno p-value reported

Based on the 100-mm VAS scale, the subjective assessment of the general health status associated with SCIG therapy showed a slightly non-significant increase compared to baseline values (65.27 ± 17.83 vs. 68.26 ± 19.78).

also in 109 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.